Navigation Links
Boiron Laboratories Disputes British Journal's Editorial on Homeopathy
Date:11/27/2007

NEWTOWN SQUARE, Pa., Nov. 27 /PRNewswire/ -- In its continued educational and research efforts for the advancement of homeopathy, Boiron Laboratories disputes an editorial comment published in The Lancet's Nov. 17, 2007 issue on the basis that its author has misinterpreted results of clinical trials on homeopathic medicines. (1-5)

The British medical journal features an editorial by Ben Goldacre on the "Benefits and Risks of Homeopathy." In his commentary, Goldacre suggests that the results from five large meta-analyses indicate that homeopathy produces no statistically significant benefit over placebo.

However, a thorough review of the studies' research evidence indicates positive principle conclusions in favor of homeopathy over placebo as quoted as follows:

1. The Kleijnen, et al(1) study states that "the evidence of clinical

trials is positive but not sufficient to draw any definite

conclusions."

2. The Boissel, et al(2) study reports that "[f]or 17 retained

comparisons, for each method used, the result is a p-value well below

.0001. This means that in at least one test, the null hypothesis (lack

of effect of homeopathy) must be rejected. ... The number of

significant results is not likely due to chance alone."

3. The Linde, et al(3) study concludes that "[t]he results of the

available randomized trials suggest that individualized homeopathy has

an effect over placebo."

4. The Cucherat, et al(4) study concludes that "[t]here is evidence that

homeopathic treatments are more effective than placebo."

5. The Shang, et al(5) study indicates that "21 (19 percent) homeopathic

trials and nine (8 percent) conventional medicine tests were of higher

quality. Most odds ratios indicated a beneficial effect of the

intervention. Heterogeneity of trial results was less pronounced for

ho
'/>"/>

SOURCE Boiron Laboratories
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
3. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
5. Sandia National Laboratories Selects Allscripts Electronic Health Record and Practice Management for Employee Health Center
6. Andrew Lessmans TWC Construction and ProCaps Laboratories Contract With DT Solar to Install a 700 kW Solar Electric System
7. Mesa Laboratories Names New Vice President of Sales and Marketing
8. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
9. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Second Quarter Earnings
10. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
11. JDRF partners with Housey Pharmaceutical Research Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Joan Lunden, award-winning ... speaker at the upcoming 32nd Annual Miami Breast ... Physicians’ Education Resource®, LLC (PER®) , shares that “a ... gone undetected if she had not followed up her ...
(Date:1/22/2015)... La Jolla, Calif. (PRWEB) January 22, 2015 ... and Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen ... (CHI) for their leadership in advancing biotechnology, biomedical ... Mitchell, Bonilla and Olsen each received the “2014 ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative ... design to treat specific body parts and muscle groups. , ... easy to use patented cold therapy machine with the innovative ... and muscle injuries. IsoComforter has become the industry leader ...
(Date:1/22/2015)... Payday lending practices in four southern ... financial distress to the states that permit them, according ... Center on Race and Wealth. , While they generate ... loans at the same time substantially depress economic activity, ...
(Date:1/22/2015)... As interest in the value of spiritual support ... Rev. Eric J. Hall , president and CEO of ... be the keynote speaker on January 27 at an international ... , The conference, “Hope and Resilience: Innovative and Interdisciplinary Spiritual ...
Breaking Medicine News(10 mins):Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... 11 The Guidebook of Sexual Medicine,was ... as the main unit for,treatment of sexual ... the thorough evaluation of biological factors (e.g., ... psychosocial factors (e.g.,presence of depression, relational conflicts, ...
... Welcome to Consumer,Reports Health News for health ... issues pertaining to the efficacy and safety,of ... health, diet and nutrition, food safety, and ... the effectiveness and affordability of,prescription drugs, and ...
... 11, 2008) The World Bank and Conservation International ... new funds, provided by the Global Environment Facility (GEF), ... threatened areas, including island ecosystems and temperate forests. , ... of all terrestrial plants and animals, as well as ...
... drugs reduce risk of major vascular events , FRIDAY, ... be considered for treatment with cholesterol-lowering statins. , That,s the ... 12 issue of The Lancet . , The British ... major vascular events in a wide range of people with ...
... offered free by LifeSpan Nutrition, SAN DIMAS, Calif., ... Family Guide To Vitamin D", which reveals,the new unfolding ... health and the health of your loved ones., ... says,achieving adequate levels of vitamin D will do more ...
... MONTREAL, Jan. 11 /PRNewswire-FirstCall/ - DRAXIS Health Inc, (TSX:,DAX) (NASDAQ: ... (TSX) to make,a Normal Course Issuer Bid (NCIB), subject to ... of the TSX., The maximum number of common shares ... such number of common shares which,represents 10% of the common ...
Cached Medicine News:Health News:A New Book on Sexual Medicine Calls Attention to 'The Couple' and Presents State-of-the Art Treatments for Sexual Dysfunction 2Health News:Consumer Reports Health News 2Health News:Consumer Reports Health News 3Health News:Consumer Reports Health News 4Health News:Global Environment partners provide additional $20 million to protect endangered habitats 2Health News:Statin Therapy Helps Diabetic Patients 2Health News:Join the Vitamin D Revolution: How to Get 30 Minutes of Daily Sunshine for Optimal Health 2Health News:DRAXIS Announces Application for Normal Course Issuer Bid 2Health News:DRAXIS Announces Application for Normal Course Issuer Bid 3Health News:DRAXIS Announces Application for Normal Course Issuer Bid 4
(Date:1/23/2015)... Ala. , Jan. 23, 2015 Gem Pharmaceuticals ... patients have been enrolled into the Company,s Phase 2 ... and safety of Gem,s lead compound, GPX-150 (an investigational ... advanced or metastatic disease. Logo - ...
(Date:1/23/2015)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... and sale of patented biopharmaceutical medicine, modernized traditional Chinese ... today announced the business and development progress at its ... Following the September 2014 JCM application (No. 51268) for ...
(Date:1/22/2015)... 2015  BiOptix is pleased to announce the appointment of ... Chemistry and Biochemistry. Scott joins the company after previous scientific ... throughout the course of his nearly 20 year career ... a nationally recognized thought leader in the biosensor field ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... 28, 2011 Reportlinker.com announces that ... available in its catalogue: ... Care Devices Market Outlook to 2017- ... http://www.reportlinker.com/p0739469/South-and-Central-America-Diabetes-Care-Devices-Market-Outlook-to-2017--Glucose-Monitoring-and-Insulin-Delivery.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ...
... MYL ) today announced that its subsidiary Mylan ... and Drug Administration (FDA) for its Abbreviated New Drug Application ... mg (base). This product is the generic version of Abbott ... hypertension. Mylan was the first company to ...
Cached Medicine Technology:South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 2South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 3South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 4South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 5South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 6South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 7South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 8South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 9Mylan Launches First Generic Version of Teveten® Tablets 2
...
...
...
Rhoton Curettes, titanium, length 191 mm, straight....
Medicine Products: